Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Dec 09, 2024 10:46am
195 Views
Post# 36352648

RE:RE:Investor Presentation [12-2024]

RE:RE:Investor Presentation [12-2024]

Nobody yet knows what the FDA is lookifor here.  No matter what they have to complete trial and get as many sites needed to do so.  If Accelerated FDA approval is granted , they will still need to complete trial for full approval as well as do a confirmatory trial.  As per FDA guidelines completion of trial ( extra 25 or so patients) can sometimes serve as a confirmatory trial if I remember correctly.  So full approval should be 2026/2027 however AA can come before.  IMHO


TommyNickels wrote: Clearly the FDA wants the study completed. They haven't recruited 4 new sites for no reason. Roger likely was gambling that 75 would be good enough. As wr have been saying, Theralase is not sufficiently bankrolled. 4 new sites and no money for new patients. 

They have to get the money and then recruit the patients. Will 25 more patients be completed by end of Q2? Doubtful, hence the 2027 deadline. 

If you are lucky, the next 25 are treated by the end of Q3 / early Q4.

 

<< Previous
Bullboard Posts
Next >>